Acute megakaryocytic leukemia: What have we learned. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Hahn, Andrew W.; Li, Bojia; Prouet, Philippe; Giri, Smith; Pathak, Ranjan; Martin, Mike G.
• Is Part Of: Blood reviews. Volume 30:Issue 1(2016:Jan.)
• Page Start: 49
• Page End: 53
• Publication Date: 2016-01
• Subjects: Acute megakaryocytic leukemia -- AML M7 -- Molecular features -- Clinical outcomes -- Allogeneic hematopoietic stem cell transplant -- Polyploidization -- Novel therapies; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2015.07.005
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.